STI Stock Trade Intelligence
OSX

OSTEOPORE LIMITED

Health Care · ASX:OSX
$0.0040
▲ +33.33%
Market cap
$2M
Turnover
$5,985
Last price
$0.0040
Day change
+33.33%
Announcements
7
Range, past year
Open 0.013 · Low 0.003 · Now 0.004 · High 0.029
Open OSX in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

OSX momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-10-13.
Momentum quality
24/100
Wyckoff phase
Accumulation8d
Trend stage
Neutral
1 Day
+33.3%
1 Week
+33.3%
1 Month
+0.0%
1 Year
-66.7%
RSI
52
Avg daily range
17.7%

OSTEOPORE LIMITED scores 24 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 8 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -40.0%
  • High volatility (ATR 17.7%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
OSX appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

OSX announcements

Recent price-sensitive releases.
  • 2026-08-31 Half Yearly Report and Accounts Half Yearly Report | Half Year Audit Review | Half Year Directors' Statement | Half Year Accounts | Half Year Directors' Report
  • 2026-08-06 OSX strikes orthopaedic deal for 5 Middle East countries Progress Report
  • 2026-07-31 Activities Report June 2026 and Appendix 4C Commitments Test Entity - Second Quarter Activity Report | Company Presentation | Commitments Test Entity - Second Quarter Cashflow Report
  • 2026-06-23 Further Drawdown of T2 of the Redeemable Convertible Notes
  • 2026-05-26 OSX secures Hainan FDA approval for orthopaedic devices
  • 2026-04-30 Activities Report March 2026 and Appendix 4C
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.